Dr Ole Tietz is a Senior Research Fellow and Group Leader at the Dementia Research Centre, Macquarie Medical School. Ole studied Chemistry at Imperial College London, UK, and completed his PhD in Oncology at the University of Alberta, Canada. He held prestigious research fellowships at the University of Cambridge and the University of Oxford. Ole is co-founder and CSO of Synaptra BIO, a Macquarie University spin-out company seeking to develop new therapeutics to treat Demenita. Ole leads the Chemistry Group at the Dementia Research Centre and works on the development of new therapeutics and diagnostics to effectively treat neurodegenerative diseases.

Ole is interested in developing novel drugs for the effective diagnosis and treatment of neurodegenerative diseases, including Dementia, Alzheimer's Disease, and Motor Neuron Disease. This includes the rational design of small molecules against protein-protein interfaces, and the development of biologics, including peptides and antibodies, to target important biomolecular pathways that drive disease progression in neurodegenerative disease. Ole aims to bring new drugs into clinical use that will help build a world without dementia.